Previous 10 | Next 10 |
Alfi (ALF) +35%.SemiLEDs Corporation (LEDS) +19%.Protagenic Therapeutics (PTIX) +18%.Party City Holdco (PRTY) +12% on Q1 results.BioNTech SE (BNTX) +9% on Q1 results.Aptorum Group Limited (APM) +8%.VYNE Therapeutics (VYNE) +8%.Inovio Pharmaceuticals (INO) +8% on positive data f...
After a critical FDA briefing doc, the advisory committee split 9-9 on efficacy, 10-8 on safety and risk-benefit. This tells me a CRL is likely because the FDA has no reason to go against its own briefing document and break the tie. Insiders have never invested in their story. ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks jumped to record levels on Friday despite a disappointing April jobs report that showed non-farm payrolls rising by only 266,000 compa...
ChemoCentryx Inc (NASDAQ: CCXI) tanked roughly 60% in the stock market on Friday as approval for its drug for an autoimmune disease hung in the balance. ChemoCentryx is seeking FDA approval for Avacopan as a treatment for Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vas...
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...
Shares of ChemoCentryx (NASDAQ: CCXI) were cratering by 58.3% as of 11:40 a.m. EDT on Friday. The stock also crashed on Tuesday after the U.S. Food and Drug Administration (FDA) released briefing documents for an advisory committee that expressed significant reservations about t...
ChemoCentryx, Inc. (NASDAQ: CCXI) reported the outcome of the United States Food and Drug Administration Arthritis Advisory Committee on avacopan to treat Antineutrophil Cytoplasmic Autoantibody associated vasculitis. In the final segment of the meetingth...
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...
ChemoCentryx hurt by a series of downgradesLate yesterday, ChemoCentryx (CCXI) announced its narrow win at the FDA’s expert panel meeting on the potential approval for avacopan in the treatment of vasculitis associated with antineutrophil cytoplasmic autoantibody ((ANCA)).At least...
ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...